Effect of depletion of Zeb1 in CD11c+ dendritic cells
Ontology highlight
ABSTRACT:
ORGANISM(S): Mus musculus
PROVIDER: GSE216059 | GEO | 2023/09/07
REPOSITORIES: GEO
Similar Datasets
Project description:To investigate potential target genes of Zeb1 that were involved in regulation of antigen cross-presentation. We then performed gene expression profiling analysis using data obtained from RNA-seq from WT and Zeb1-deficient BMDC after HKLM-OVA stimulating for 4 hours.
2023-09-07 | GSE206963 | GEO
Project description:To investigate potential target genes of Zeb1 that were involved in regulation of antigen cross-presentation. We then performed CUT&tag about Zeb1 gene from WT BMDC after HKLM-OVA stimulating for 4 hours
2023-09-07 | GSE206964 | GEO
Project description:To investigate potential target miRNA of Zeb1 that were involved in regulation of antigen cross-presentation. We then performed gene expression profiling analysis using data obtained from miRNA-seq from WT and Zeb1-deficient BMDC after HKLM-OVA stimulating for 4 hours.
2023-09-07 | GSE207161 | GEO
Project description:Antigen uptake, processing and presentation by dendritic cells are regulated by complex intra- and inter-cellular signalling events. Typical vaccine adjuvants lead to the transcription of pro-inflammatory cytokines and chemokines which relate to immune induction. We used microarrays to detail the global expression of genes in BMDC underlying emulsion internalization and DC activation with a non-inflammatory nanoemulsion adjuvant. BMDC were incubated with 0.001% v/v naomeulsion (W805EC) or media alone for 6 hours. Total RNA was extracted per sample using RNA easy (Qiagen).
2010-11-18 | E-GEOD-25485 | biostudies-arrayexpress
Project description:Here we used a newly identified Sec61 blocker, mycolactone, to analyze Sec61 contribution to antigen cross presentation, ERAD and transport of internalized antigens into the cytosol in dendritic cells. Shotgun proteomics were used to asses the broad-ranging effects of Sec61 blockade on dendritic cells and its effect on critical proteins required for antigen presentation and ERAD.
2017-07-11 | PXD006103 | Pride
Project description:Antigen uptake, processing and presentation by dendritic cells are regulated by complex intra- and inter-cellular signalling events. Typical vaccine adjuvants lead to the transcription of pro-inflammatory cytokines and chemokines which relate to immune induction. We used microarrays to detail the global expression of genes in BMDC underlying emulsion internalization and DC activation with a non-inflammatory nanoemulsion adjuvant.
2010-11-18 | GSE25485 | GEO
Project description:Cross-presentation of tumor antigens by dendritic cells (DCs) is crucial to prime and (re-) stimulate CD8+ T cells. This process is important in initiating and maintaining an anti-tumor response. Here, we show that tumor presence of conventional type 1 DCs (cDC1), a subtype that excels in cross-presentation, correlates with response to neoadjuvant immune checkpoint blockade (ICB) in melanoma. This led us to hypothesize that patients failing to respond to ICB could benefit from enhanced cross-presentation of tumor antigens. We therefore established a cross-presentation assay to screen over 5,500 compounds for enhancers of DC cross-presentation using induced T cell proliferation as readout. We identified 145 enhancers, including AZD5582, an antagonist of inhibitor of apoptosis proteins (IAPs) cIAP1, cIAP2 and XIAP. AZD5582 treatment led to DC activation of the non-canonical nuclear factor kappa B (NF-kB) pathway, enhanced antigen import from endolysosomes into the cytosol and increased expression of genes involved in cross-presentation. Furthermore, it upregulated expression of CD80, CD86, MHC class II, CD70 and secretion of TNF by DCs. This enhanced DC activation and maturation program was observed also in tumor-bearing mice upon AZD5582 treatment, culminating into an increased frequency of systemic tumor antigen-specific CD8+ T cells. Our results merit further exploration of AZD5582 to increase antigen cross-presentation for improving the clinical benefit of ICB in unfavorable patients.
2023-03-23 | GSE217050 | GEO
Project description:Cross-presentation of tumor antigens by dendritic cells (DCs) is crucial to prime and (re-) stimulate CD8+ T cells. This process is important in initiating and maintaining an anti-tumor response. Here, we show that tumor presence of conventional type 1 DCs (cDC1), a subtype that excels in cross-presentation, correlates with response to neoadjuvant immune checkpoint blockade (ICB) in melanoma. This led us to hypothesize that patients failing to respond to ICB could benefit from enhanced cross-presentation of tumor antigens. We therefore established a cross-presentation assay to screen over 5,500 compounds for enhancers of DC cross-presentation using induced T cell proliferation as readout. We identified 145 enhancers, including AZD5582, an antagonist of inhibitor of apoptosis proteins (IAPs) cIAP1, cIAP2 and XIAP. AZD5582 treatment led to DC activation of the non-canonical nuclear factor kappa B (NF-kB) pathway, enhanced antigen import from endolysosomes into the cytosol and increased expression of genes involved in cross-presentation. Furthermore, it upregulated expression of CD80, CD86, MHC class II, CD70 and secretion of TNF by DCs. This enhanced DC activation and maturation program was observed also in tumor-bearing mice upon AZD5582 treatment, culminating into an increased frequency of systemic tumor antigen-specific CD8+ T cells. Our results merit further exploration of AZD5582 to increase antigen cross-presentation for improving the clinical benefit of ICB in unfavorable patients.
2023-03-23 | GSE217048 | GEO
Project description:To investigate whether pharmacological stimulation of mesenchymal stromal cells (MSCs) could induce cross-presentation abilities, we treated MSCs with A1. We performed gene expression profiling analysis using data obtained from RNA-seq of untreated MSCs, MSCs treated only with the molecule A1, and MSCs treated with the molecule A1 and the model antigen ovalbumin. A1 is an Accum™ variant, a molecule design to enhance intracellular accumulation of associated molecules through endosomal disruption. Endosomal break was targeted for its crucial role in antigen export to the cytosol and cross-presentation of endocytosed antigen.
2024-01-31 | GSE247278 | GEO
Project description:Immune evasion is an important hallmark of cancer ensured by diverse strategies, including immunosuppression and downregulation of antigen presentation. Here, to restore immunogenicity of cancer cells, we employed the minimal gene regulatory network of highly immunogenic type 1 conventional dendritic cells (cDC1) to reprogram cancer cells into professional antigen presenting cells (APCs). We showed that enforced expression of PU.1, IRF8 and BATF3 (PIB) was sufficient to induce cDC1 phenotype in 33 cell lines derived from human and mouse hematological and solid tumors. PIB gradually modified the cancer cell transcriptional and epigenetic program imposing global antigen presentation and cDC1 gene signatures within 9 days. cDC1 reprogramming restored the expression of antigen presentation complexes as well as co-stimulatory molecules at the cell surface, leading to the presentation of endogenous antigens on MHC-I, and to CD8+ T cell mediated killing. Functionally, tumor- APCs acquired the ability to uptake and process exogenous proteins and dead cells, secreted inflammatory cytokines and cross-presented antigens to naïve CD8+ T cells. Importantly, tumor-APCs were efficiently generated at the single cell level from primary cancer cells of 7 solid tumors that presented antigens to memory and naïve T-cells, as well as to activated patient-specific intra-tumoral lymphocytes. Alongside antigen presentation, tumor-APCs harboring TP53, KRAS and PTEN mutations showed impaired tumorigenicity in vitro and in vivo. Finally, using in vivo mouse models of melanoma, we showed that intra-tumoral injection of tumor-APCs promoted lymphoid infiltration, delayed tumor growth and increased survival. The anti-tumor immunity elicited by tumor-APCs was synergistic with immune checkpoint inhibitors enabling tumor eradication. Our approach combines cDC1’s antigen processing and presenting abilities with endogenous generation of tumor antigens and serves as a platform for the development of novel immunotherapies based on endowed antigen presentation in cancer cells.
2023-10-24 | PXD039789 | Pride